212 related articles for article (PubMed ID: 14752084)
1. Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference.
Herold R; von Stackelberg A; Hartmann R; Eisenreich B; Henze G
J Clin Oncol; 2004 Feb; 22(3):569-70; author reply 570-1. PubMed ID: 14752084
[No Abstract] [Full Text] [Related]
2. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
4. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
6. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
Schrauder A; Reiter A; Gadner H; Niethammer D; Klingebiel T; Kremens B; Peters C; Ebell W; Zimmermann M; Niggli F; Ludwig WD; Riehm H; Welte K; Schrappe M
J Clin Oncol; 2006 Dec; 24(36):5742-9. PubMed ID: 17179108
[TBL] [Abstract][Full Text] [Related]
7. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
8. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.
Stanulla M; Cario G; Meissner B; Schrauder A; Möricke A; Riehm H; Schrappe M
Blood Cells Mol Dis; 2007; 39(2):160-3. PubMed ID: 17532236
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group.
Reismüller B; Attarbaschi A; Peters C; Dworzak MN; Pötschger U; Urban C; Fink FM; Meister B; Schmitt K; Dieckmann K; Henze G; Haas OA; Gadner H; Mann G;
Br J Haematol; 2009 Feb; 144(4):559-70. PubMed ID: 19077160
[TBL] [Abstract][Full Text] [Related]
10. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Münster Chemotherapy in Adult Acute Lymphoblastic Leukemia.
Aladag E; Aktimur SH; Aydın Ö; Demiroglu H; Buyukasik Y; Aksu S; Ozcebe OI; Haznedaroglu IC; Sayinalp N; Turgut M; Goker H
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):147-153. PubMed ID: 33451957
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a meta-analysis.
Bartolozzi B; Bosi A; Orsi C
Cancer; 2007 Jan; 109(2):343; author reply 344. PubMed ID: 17154182
[No Abstract] [Full Text] [Related]
13. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies.
Biondi A; Rizzari C; Valsecchi MG; De Lorenzo P; Aricò M; Basso G; Locatelli F; Lo Nigro L; De Rossi G; Masera G
Haematologica; 2006 Apr; 91(4):534-7. PubMed ID: 16537119
[TBL] [Abstract][Full Text] [Related]
14. Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.
Borgmann A; Zinn C; Hartmann R; Herold R; Kaatsch P; Escherich G; Möricke A; Henze G; von Stackelberg A;
Eur J Cancer; 2008 Jan; 44(2):257-68. PubMed ID: 17981026
[TBL] [Abstract][Full Text] [Related]
15. ALL-BFM 95 treatment in Turkish children with acute lymphoblastic leukemia--experience of a single center.
Kocak U; Gursel T; Kaya Z; Aral YZ; Albayrak M; Keskin EY; Belen B; Isık M; Oner N
Pediatr Hematol Oncol; 2012 Mar; 29(2):130-40. PubMed ID: 22376016
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ
Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group.
Matsuzaki A; Nagatoshi Y; Inada H; Nakayama H; Yanai F; Ayukawa H; Kawakami K; Moritake H; Suminoe A; Okamura J
Pediatr Blood Cancer; 2005 Aug; 45(2):111-20. PubMed ID: 15782402
[TBL] [Abstract][Full Text] [Related]
18. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) study group.
Reismüller B; Peters C; Dworzak MN; Pötschger U; Urban C; Meister B; Schmitt K; Dieckmann K; Gadner H; Attarbaschi A; Mann G;
J Pediatr Hematol Oncol; 2013 Jul; 35(5):e200-4. PubMed ID: 23652878
[TBL] [Abstract][Full Text] [Related]
19. [Treatment strategy for adult acute lymphoblastic leukemia].
Okamoto S
Rinsho Ketsueki; 2002 Jun; 43(6):427-32. PubMed ID: 12134694
[No Abstract] [Full Text] [Related]
20. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
